Skip to main content

A closer look into biotech dealmaking

In recent quarters, dealmaking has picked up noticeably, despite there not being any big-ticket acquisitions. The cash holdings of several large pharmaceutical companies have also swelled, giving them greater resources to pursue dealmaking.

included in this trendline
  • After a lengthy drought, could biotech M&A be on the upswing?
  • The top questions facing biotech M&A in 2022
  • Venture investors turn to safer bets after biotech correction
Our Trendlines go deep on the biggest trends. These special reports, produced by our team of award-winning journalists, help business leaders understand how their industries are changing.
Davide Savenije Editor-in-Chief at Industry Dive.